Taken together, the results of this pilot investigation demonstrate that urinary excretion of AQP2 and AQP5 might represent a novel urine proteomic signature able to reliably identify diabetic patients with DN using a noninvasive approach. This evidence concerns the gene AQP2 and liver dysplastic nodule.